Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy ...

A federal judge in North Carolina on Tuesday granted an order for summary judgment in favor of Merck (NYSE:MRK) regarding lawsuits accusing the drugmaker of failing to warn consumers its Gardasil ...

The drugmaker Merck announced it has opened a $1 billion vaccine manufacturing facility in north Durham, a 225,000-square-foot addition to the company’s existing campus off Old Oxford Road.

At its sprawling complex in Durham, N.C., Merck has opened a new $1 billion, 225,000-square-foot manufacturing plant slated to produce bulk substance for its megablockbuster HPV vaccine Gardasil.

Merck has opened a $1 billion, 225,000-square-foot facility at its Durham campus dedicated to vaccine manufacturing, the drug giant announced Tuesday. Merck has opened a $1 billion, 225,000-square ...

(Reuters) -Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, as the drugmaker seeks to boost its U.S. manufacturing in the face of President Donald Trump's ...

DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...

Opening highlights effort to expand U.S. manufacturing through a $1 billion investment DURHAM, N.C., March 11, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States ...

March 11 (Reuters) - Merck (MRK.N), opens new tab said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid ...

STORY HIGHLIGHTS Merck opens new vaccine facility in Durham. New facility will manufacture HPV vaccines Gardasil and Gardasil 9. Merck plans to invest $8 billion more in U.S. by 2028. A global ...

Merck KGaA is continuing development of its lupus therapy despite the negative announcement. Image credit: ricochet64 / Shutterstock. Merck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet ...

Both Merck & Co. and Halozyme are holding their ground in a freshly unveiled patent dispute surrounding the New Jersey pharma’s under-the-skin version of its blockbuster cancer drug Keytruda.